Articles from OpZira, Inc.

OpZira™, Inc., an ophthalmic medical device company advancing technologies for the detection and monitoring of ocular disease, today announced its selection to present at the 2026 New York Venture Summit, taking place November 18-19 at the Javits Center in New York City.

OpZira™, Inc., an ophthalmic medical device company advancing technologies for the detection and monitoring of ocular disease, today announced its subsidiary, AdaptDx, Inc., has completed its Stage II audit at the company's Lighthouse medical device manufacturing facility. The audit represents an important step in the ISO certification process and supports OpZira's plans to pursue CE marking for AdaptDx Pro® in the European Union in 2027.

OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced that Scott Thielman, PhD, PE, has joined the company as Vice President of Product Development, effective May 1, 2026.

OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools.